CapsoVision Q2 revenue $3.6M (+10% YoY), gross margin 51%, ATM up to $100M

CapsoVision, Inc

Q2 revenue $3.6M, up 10% YoY; gross margin 51% vs 55% on pricing pressure and tariffs.
Operating expenses $9.5M, up $3.0M YoY; cash $9.1M at June 30, 2026.
Entered ATM equity offering up to $100M with Cantor Fitzgerald; 3% commission.
Launched AI Highlights™ internationally; FDA clearance expected by end of Q3 2026.
Appointed David S. Shields, M.D. to Board effective July 1, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.